Kiora Pharmaceuticals INC Form 4 insider transactions

Erin Parsons, a director at Kiora Pharmaceuticals, acquired stock options to purchase 1,778 shares of common stock on July 1, 2024, according to a Form 4 filing.

Director Aron Shapiro acquired stock options in Kiora Pharmaceuticals through the company's 2024 Equity Incentive Plan.

Lisa Walters-Hoffert, a director of Kiora Pharmaceuticals, acquired stock options to purchase 1,778 shares of common stock on July 1, 2024.

Director David Hollander of Kiora Pharmaceuticals acquired stock options on July 1, 2024, under the company's 2024 Equity Incentive Plan.

Director Praveen Tyle acquired stock options in Kiora Pharmaceuticals, according to a Form 4 filing.

Melissa Tosca, EVP Finance at Kiora Pharmaceuticals, reports purchasing 100 shares of common stock at $5.25 per share on June 14, 2024.

Eric Joseph Daniels, Chief Development Officer of Kiora Pharmaceuticals, recently acquired 1,431 shares of common stock at a price of $5.29 per share.

Erin Parsons, a director of Kiora Pharmaceuticals, indirectly acquired 5,260 shares of common stock through a purchase by their spouse on June 13, 2024.

Kiora Pharmaceuticals' CEO, Brian M. Strem, purchased 3,000 shares of the company's common stock at a price of $4.999 per share on June 13, 2024.